Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic-Reference-Cited by-同舟云学术

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Published:2015-12-26 Issue:1 Volume:18 Page:
ISSN:1092-8480
Container-title:Current Treatment Options in Neurology
language:en
Short-container-title:Curr Treat Options Neurol

Author:

Kessler Remi A.,Mealy Maureen A.,Levy Michael

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical)

Link

http://link.springer.com/content/pdf/10.1007/s11940-015-0387-9.pdf

Reference65 articles.

1. Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int. 2012;2012:460825. doi: 10.1155/2012/460825 .

2. Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665–71. doi: 10.1212/WNL.0b013e318248dec1 . discussion 9.

3. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–80. doi: 10.1001/archneurol.2012.314 .

4. Pereira WL, Reiche EM, Kallaur AP, Kaimen-Maciel DR. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review. J Neurol Sci. 2015;355(1–2):7–17. doi: 10.1016/j.jns.2015.05.034 .

5. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–7. doi: 10.1084/jem.20050304 .

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review;Multiple Sclerosis and Related Disorders;2024-11

2. Neuromyelitis Optica: A Deceiving Disorder of Demyelination;Cureus;2024-07-22

3. Atypical presentation of biotinidase deficiency: masquerading neuromyelitis optica spectrum disorder;BMJ Case Reports;2024-07

4. The risk of type 2 diabetes mellitus in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study;Multiple Sclerosis and Related Disorders;2024-05

5. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database;Multiple Sclerosis and Related Disorders;2024-04